Chinook Therapeutics, Inc. (KDNY)
Market Cap | 1.57B |
Revenue (ttm) | 56.85M |
Net Income (ttm) | -117.77M |
Shares Out | 63.94M |
EPS (ttm) | -1.70 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 80,553 |
Open | 25.18 |
Previous Close | 25.27 |
Day's Range | 24.30 - 25.48 |
52-Week Range | 11.81 - 27.44 |
Beta | 0.36 |
Analysts | Buy |
Price Target | 37.17 (+51.47%) |
Earnings Date | Mar 16, 2023 |
About KDNY
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the t... [Read more]
Financial Performance
In 2021, KDNY's revenue was $51.63 million, an increase of 6142.44% compared to the previous year's $827,000. Losses were -$102.94 million, 26.1% more than in 2020.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for KDNY stock is "Buy." The 12-month stock price forecast is $37.17, which is an increase of 51.47% from the latest price.
News

Chinook Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
SEATTLE, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for...

Chinook Therapeutics to Present at Upcoming Investor Conferences
SEATTLE, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for...

Chinook Therapeutics (KDNY) Reports Q3 Loss, Tops Revenue Estimates
Chinook (KDNY) delivered earnings and revenue surprises of -33.87% and 614.57%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Chinook Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
SEATTLE, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for...

Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and CHK-336 Preclinical Efficacy Data at the American Society of Nephrology (ASN) Kidney Week 2022
SEATTLE, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for...

Chinook Therapeutics Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort, Preclinical Atrasentan Research and Ongoing Clinical Trials at the American Society of Nephrology (ASN) Kidney Week 2022
SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for...

Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the American Society of Nephrology (ASN) Kidney Week 2022
SEATTLE, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for...

Chinook Therapeutics (KDNY) Reports Q2 Loss, Misses Revenue Estimates
Chinook (KDNY) delivered earnings and revenue surprises of 1.61% and 83.28%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Chinook Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for...

Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SEATTLE, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for...

Chinook (KDNY) Is a Great Choice for "Trend" Investors, Here's Why
Chinook (KDNY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Here's Why Chinook Therapeutics (KDNY) is a Great Momentum Stock to Buy
Does Chinook Therapeutics (KDNY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why "Trend" Investors Would Love Betting on Chinook (KDNY)
Chinook (KDNY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Chinook (KDNY) Stock Rallies 24.2% in 3 Months: Here's Why
Despite no marketable drugs in its portfolio, Chinook (KDNY) is progressing well with its pipeline. Updated data from a study supports the potential clinical utility of BION-1301 in the IgA nephropath...

4 Small Stocks to Bet on in an Upbeat Drugs Industry
It is expected that innovation will continue to drive growth in the Medical-Drugs industry in 2022. KDNY, ASRT, VIRX, SLNO may prove to be good additions to one's portfolio.

Chinook Therapeutics to Present at the William Blair Biotech Focus Conference 2022
SEATTLE, July 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for...

Chinook Therapeutics Receives Orphan Drug Designation from European Commission for BION-1301 for Treatment of Primary IgA Nephropathy (IgAN)
SEATTLE, July 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for...

Here's Why Momentum in Chinook (KDNY) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, Chinook (KDNY) could be a great choice. It is one of the several stocks that passed through our "Recent Price S...

Wall Street Analysts See a 94% Upside in Chinook (KDNY): Can the Stock Really Move This High?
The consensus price target hints at a 93.8% upside potential for Chinook (KDNY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate ...

Recent Price Trend in Chinook (KDNY) is Your Friend, Here's Why
Chinook (KDNY) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our sh...

Does Chinook (KDNY) Have the Potential to Rally 110% as Wall Street Analysts Expect?
The mean of analysts' price targets for Chinook (KDNY) points to a 109.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst...

Chinook Therapeutics Announces Pricing of a $105 Million Public Offering
SEATTLE, May 24, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced the pricing of its underwritten public offering of 6,428,572 shares of its common stock at a price t...

Chinook Therapeutics Announces Proposed Public Offering
SEATTLE, May 24, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ...

Chinook (KDNY) Upgraded to Buy: What Does It Mean for the Stock?
Chinook (KDNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).